GlaxoSmithKline plc CEO Emma Walmsley received about £4.9 million total remuneration in 2017.
Walmsley received about £3.5 million in performance-based pay, in addition to the £1.4 million fixed pay the company granted.
In comparison, former GlaxoSmithKline CEO Andrew Witty's total remuneration in 2016 was about £6.8 million.
Walmsley has been CEO of the U.K.-based drugmaker since March 31, 2017.
The company said it will disclose the pay ratio between CEO and the average of its U.K. employees when the method for computing the ratio is finalized in new regulations.
